We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

YB:NASDAQYuanbao Inc. Analysis

Data as of 2026-09-09 - not real-time

$13.49

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Yuanbao Inc. trades at $13.48, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Across the trailing 30 sessions it lost 4.9%. With RSI at 46.2 the momentum picture is neutral, alongside a bullish MACD signal. The recent range runs from support at $12.11 up to resistance at $14.39.
On valuation the read is undervalued — earnings multiple of 3.2 versus a 33.3 sector average, below the peer group. The average analyst target implies 34.3% above today's level. Revenue is growing at 35.6% on a 29.7% profit margin. The 9.33% dividend yield looks covered by current payout levels.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 42.2%, a beta of 0.67 and a maximum drawdown of 51.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.

Top Market Events

Yuanbao Inc. will announce its Q2 2026 financial results on September 10, followed by a conference cDetailed price information for Yuanbao Inc ADR YB-Q from The Globe and Mail including charting and trades.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 17.21
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 3.2 versus sector average of 33.3
  • Trading below the 200-day average of 17.21

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 3.2 versus sector average of 33.3
  • Analyst targets imply +34.3% versus the current price
  • Profit margin of 29.7% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth35.60%
Profit Margin29.67%
P/E Ratio3.2
ROE47.88%
ROA21.31%
Debt/Equity0.11
P/B Ratio1.1
Industry P/E33.3

Technical Analysis

TrendBearish
RSI46.2
Support$12.11
Resistance$14.39
MA 20$13.68
MA 50$13.94
MA 200$17.21
MACDBullish
VolumeDecreasing
Fear & Greed Index92.02

Valuation

Target Price$18.12
Upside/Downside34.35%
GradeUndervalued
TypeValue
Dividend Yield9.33%

Risk Assessment

Beta0.67
Volatility42.18%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.